Medicinal Products

Dáil Éireann Debate, Tuesday - 22 September 2026

• Díospóireachtaí
• Aimsigh díospóireacht
  • Díospóireachtaí na Dála
  • Díospóireachtaí an tSeanaid
  • Díospóireachtaí Coiste
• Aimsigh vótáil
  • Vótálacha na Dála
  • Vótálacha an tSeanaid
  • Vótálacha Coiste
• Ceisteanna Parlaiminte
  • Ceisteanna scríofa
  • Ceisteanna ó bhéal
• Leideanna cuardaigh
• Nuair a bhíonn tionchar tromchúiseach ag aithrisí

Tuesday, 22 September 2026

Ceisteanna (554)

Ken O'Flynn

Ceist:

554. Deputy Ken O'Flynn asked the Minister for Health whether the HSE monitored the substitution between nebulised products (details supplied) during the supply shortages affecting these medicines in 2025 and 2026; and the steps taken to ensure continuity of treatment for affected patients. [66545/26]

Freagraí scríofa

Minister for Health

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.

• An Freagra Roimhe Sin
• An Chéad Fhreagra eile